QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, H. M. Articles by Houston, J. B. Search for Related Content PubMed PubMed Citation Articles by Jones, H. M. Articles by Houston, J. B.

QUANTITATIVE PREDICTION OF THE IN VIVO INHIBITION OF DIAZEPAM METABOLISM BY OMEPRAZOLE USING RAT LIVER MICROSOMES AND HEPATOCYTES

Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom

The diazepam (DZ)-omeprazole (OMP) interaction has been selected as a prototype for an important drug-drug interaction involving cytochrome P450 inhibition. The availability of an in vivo K_i value (unbound K_i, 21 µM) obtained from a series of steady-state inhibitor infusion studies allowed assessment of several in vitroderived predictions of this inhibition interaction. Studies monitoring substrate depletion with time were used to obtain in vitro K_i values that were evaluated against the more traditional metabolite formation approach using microsomes and hepatocytes. OMP inhibited the metabolism of DZ to its primary metabolites 4'-hydroxydiazepam, 3-hydroxydiazepam, and nordiazepam to different extents over a range of concentrations (0.3–150 µM), and a competitive inhibition model best fitted the data. The K_i values observed using the substrate depletion approach (16 ± 3 µM and 7 ± 2 µM in microsomes and hepatocytes, respectively) were in good agreement with the overall weighted K_i values obtained using the standard metabolite formation approach (12 ± 2 µM and 16 ± 5 µM in microsomes and hepatocytes, respectively). In vitro binding and cell uptake studies as well as human serum albumin studies in hepatocytes confirmed the importance of both intracellular and extracellular unbound concentrations of inhibitor when considering inhibition predictions. Both kinetic approaches and both in vitro systems predicted the in vivo interaction well and provide a good example of the ability of in vitro inhibition studies to quantitatively predict an in vivo drug-drug interaction successfully.

This article has been cited by other articles:

				K. Grime, P. J. H. Webborn, and R. J. Riley Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678. [Abstract] [Full Text] [PDF]

				H. S. Brown, A. Chadwick, and J. B. Houston Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination Drug Metab. Dispos., November 1, 2007; 35(11): 2119 - 2126. [Abstract] [Full Text] [PDF]

				Y. Mano, T. Usui, and H. Kamimura Comparison of Inhibition Potentials of Drugs against Zidovudine Glucuronidation in Rat Hepatocytes and Liver Microsomes Drug Metab. Dispos., April 1, 2007; 35(4): 602 - 606. [Abstract] [Full Text] [PDF]

				M. A. Bukys, P. Y. Kim, M. E. Nesheim, and M. Kalafatis A Control Switch for Prothrombinase: CHARACTERIZATION OF A HIRUDIN-LIKE PENTAPEPTIDE FROM THE COOH TERMINUS OF FACTOR Va HEAVY CHAIN THAT REGULATES THE RATE AND PATHWAY FOR PROTHROMBIN ACTIVATION J. Biol. Chem., December 22, 2006; 281(51): 39194 - 39204. [Abstract] [Full Text] [PDF]

				D. Hallifax and J. B. Houston Uptake and Intracellular Binding of Lipophilic Amine Drugs by Isolated Rat Hepatocytes and Implications for Prediction of in Vivo Metabolic Clearance Drug Metab. Dispos., November 1, 2006; 34(11): 1829 - 1836. [Abstract] [Full Text] [PDF]

				D. Hallifax and J. B. Houston BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT Drug Metab. Dispos., April 1, 2006; 34(4): 724 - 726. [Full Text] [PDF]

				X. Song, Y. Li, J. Liu, M. Mukundan, and B. Yan Simultaneous Substitution of Phenylalanine-305 and Aspartate-318 of Rat Pregnane X Receptor with the Corresponding Human Residues Abolishes the Ability to Transactivate the CYP3A23 Promoter J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 571 - 582. [Abstract] [Full Text] [PDF]

				H. M. Jones and J. B. Houston SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS Drug Metab. Dispos., September 1, 2004; 32(9): 973 - 982. [Abstract] [Full Text] [PDF]